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Trends for Coronary Heart Disease in Japan
In a recent article in Circulation' on the risk factors responsible for the decrease in stroke in Japan and the accompanying editorial comment,2 the possible role of fish intake was not mentioned. Fish is a major source of omega-3 fatty acids, which have an important antithrombotic effect and increase the bleeding tendency.3 These omega-3 fatty acids have only a modest influence on serum cholesterol levels but important effects on platelet function. A high level of fish intake in a population with high blood pressure could explain the high stroke level in the past in Japan. This study by Shimamoto and coworkers' shows a decrease in fat intake from fish by 38% (3 g daily) from 1969 to 1980-1983. It appears that this decrease in fish intake, coupled to a decrease in salt intake that results in a lower blood pressure, could be major factors in the decrease of hemorrhagic stroke in Japan. This hypothesis could be tested by comparing the stroke mortality and the level of fish consumption, if possible adjusted for salt intake, in the different prefectures of Japan. A positive association with hemorrhagic stroke and a negative one with thrombotic stroke could be expected. It is also interesting to note that the opposite is occurring in Hungary, where stroke, presumably thrombotic, has increased markedly since 1968, and this parallels an increase in saturated fat intake. 4 We agree with the authors that studying the ongoing changes in Japan (and Hungary) could markedly enhance our knowledge on the origin of stroke and have major public health implications. We can only hope that more such studies will be published in the future.
Reply
We appreciate Dr. Kesteloot's comments on our recent article' emphasizing the importance of observational studies in raising hypotheses and addressing public health implications. He raised the hypothesis that a decrease in fish intake, coupled with a decrease in salt intake, could be major factors in the decrease in hemorrhagic stroke in Japan. We agree that the decrease in salt intake may contribute in part to the decline in hemorrhagic stroke. However, the hypothesis on fish intake was unexpected for us because we believe that there have been no epidemiologic data in Japan to support it. It has been reported since the 1950s that stroke mortality was generally lower in coastal areas (areas of a higher fish intake) than inland areas (areas of a lower fish intake) and that average salt intake did not differ.2 A recent report showed that standardized mortality rates from all strokes, cerebral hemorrhage and cerebral infarction, were lower in coastal areas than inland areas.3 Our collaborative study between 1981 and 1983 indicated that incidence rates of both cerebral hemorrhage and infarction for men 40-69 years old were not different between fishermen and residents of farming villages, even though the average fish intake was much higher in fishermen-about 300 g/day for fishermen versus 100 g/day for farmers. 4 Furthermore, careful interpretation is needed for trends in fish intake in Japan. In our study,' the nutrition data in 1969 were obtained by a weighing method, whereas the data in the later periods were by 24-hour dietary recalls. Fish intake in 1967 may have been overestimated because the participants in the 1969 nutrition study were volunteers from relatively affluent families.
Thus, our data did not support a declining trend in fish intake. The National Nutrition Survey5 showed that average fish intake per capita per day was 87 g in 1969, 94 g in 1975, and 93 g in 1983 with no clear trend since 1969. Although these findings are not supportive of the hypothesis that fish intake was lowered and might have contributed to the reduction of hemorrhagic stroke, the hypothesis that a high fish intake might raise the risk of hemorrhagic stroke remains to be examined. 
Aspirin and Prostacyclin Synthesis in Humans
The effects of aspirin on bleeding time 6-keto-prostaglandin (PG)F1,, production in humans were recently reported in Circulation.' A 65% inhibition of prostacyclin production in bleeding time blood 24 hours after administration of 600 mg aspirin is at variance with our data that show a recovery of the in vivo formation of prostacyclin within 3-4 hours after administration of 1 g aspirin. 2 The major difference between these studies is the methodology used. Gerrard et all assessed prostacyclin production by measuring 6-keto-PGFla, the hydrolysis product of prostacyclin, in bleeding time blood with an enzyme-linked immunoassay technique. We have used gas chromatography and mass spectrom-etry with deuterated internal standards for determining the major urinary metabolite of prostacyclin, 2,3 -dinor-6 -keto-PGFi, .3 It is a well-known fact that even mild trauma to a vessel wall can cause release of prostacyclin, which then rapidly undergoes hydrolysis to 6-keto-PGFia.4 Therefore, levels of 6-keto-PGFla in plasma or in bleeding time blood do not represent the in vivo synthesis of prostacyclin. One way of circumventing problems of artifactual formation during sampling is by measuring enzymatically formed metabolites, such as 2,3-dinor-6-keto-PGF1<, in plasma or preferably in urine. 5 Gerrard et all found a significant inhibition of 6-keto-PGFi,, production 24 hours after the first dose of 325 mg aspirin but no reduction 4 hours after the 14th 325 mg tablet taken 2 weeks later. Their data, therefore, suggest both a rapid (within 4 hours) and a slow (about 2 days) recovery of prostacyclin synthesis after inhibition by aspirin. These findings are contradictory and difficult to interpret.
Our studies use approaches that bypass the problem of artifactual formation of prostacyclin during sampling and show that the in vivo synthesis of prostacyclin is inhibited 3-4 hours after an oral dose of aspirin.2 Thus, aspirin inhibits prostacyclin synthesis as long as it is present in the circulation. Aspirin blocks prostacyclin synthesis by an irreversible inactivation of the enzyme cyclooxygenase; to regain prostacyclin synthesis, cells must, therefore, synthesize new enzyme. 6 The reason for the rapid recovery of prostacyclin synthesis after inhibition by aspirin is probably a rapid production of new cyclooxygenase in the endothelial cells. This is supported by in vitro studies showing that prostacyclin synthesis is recovered rapidly with a half-time of 30-40 minutes after aspirin removal from the medium.7
Our data on the short-lasting effect of aspirin on prostacyclin synthesis have therapeutic implications. Because the synthesis of thromboxane A2 is reduced up to 10 days after a single dose of aspirin, an intermittent dose of aspirin (e.g., 500 mg every third day) should preserve the desired inhibitory effect on thromboxane formation with only minimal disturbance of prostacyclin production. 5 We have recently shown that 500 mg aspirin every third day suppresses thromboxane synthesis continuously without noticeably affecting prostacyclin formation in patients with acute myocardial infarction.8 Thus, intermittent treatment with aspirin has a favorable biochemical efficacy, and this regimen needs to be tested in large clinical trials. The preliminary report from the ongoing Physicians' Health Study, showing a prophylactic effect of an intermittent aspirin regimen in reducing the risk of myocardial infarction in healthy subjects, focuses on the potential of such therapy.9 0. Vesterqvist, PhD K. Gr6en, MD, PhD Department of Clinical Chemistry and Blood Coagulation Karolinska Hospital Stockholm Sweden
